Cigna gains as managed-care sentiment improves on softer cost-trend hopes

The Cigna Group (CI) is up 3.0% today. Here is some analysis on what might have caused this price movement.

Analysis: CI appeared to move with a broader managed-care bounce as investors leaned into signs that medical utilization and cost trends may be moderating, improving the outlook for insurer margins. Separately, a recent change to the company’s own employee benefit design around GLP-1 obesity drugs may have reinforced a near-term cost-control narrative.

Details:

Managed-care stocks rallied recently after a wave of bullish analyst commentary focused on easing utilization and potential margin recovery across large insurers.

Cigna’s first-quarter 2026 update highlighted solid operating performance and included a higher full-year adjusted earnings outlook, supporting the idea of resilient fundamentals into 2026.

Cigna’s employee health plan is expected to stop covering certain GLP-1 weight-loss drugs for obesity effective July 1, a move investors may interpret as a benefit-cost containment step (though it applies to employees rather than all customers).

Industry commentary in mid-May pointed to potentially decelerating medical cost trend versus the prior two years, which can be a direct tailwind for insurer earnings if it persists.

Sources:

Reuters, The Cigna Group (press release), 24/7 Wall St.

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$CI Insider Trading Activity

$CI insiders have traded $CI stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $CI stock by insiders over the last 6 months:

DAVID CORDANI (Chairman & CEO) has made 0 purchases and 13 sales selling 201,878 shares for an estimated $59,114,186.
NICOLE S JONES (See Remarks) sold 2,307 shares for an estimated $666,515
EVERETT NEVILLE (See Remarks) sold 1,719 shares for an estimated $496,636

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$CI Hedge Fund Activity

We have seen 798 institutional investors add shares of $CI stock to their portfolio, and 775 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 3,738,636 shares (-99.9%) from their portfolio in Q4 2025, for an estimated $1,028,984,786
PRICE T ROWE ASSOCIATES INC /MD/ removed 3,697,370 shares (-59.0%) from their portfolio in Q1 2026, for an estimated $969,043,703
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 3,142,412 shares (-99.3%) from their portfolio in Q1 2026, for an estimated $823,594,761
SANDERS CAPITAL, LLC added 2,489,293 shares (+31.9%) to their portfolio in Q1 2026, for an estimated $652,418,802
DAVIS SELECTED ADVISERS added 1,481,077 shares (+196.7%) to their portfolio in Q1 2026, for an estimated $388,175,470
JPMORGAN CHASE & CO removed 1,030,980 shares (-15.5%) from their portfolio in Q4 2025, for an estimated $283,756,625
AQR CAPITAL MANAGEMENT LLC added 989,015 shares (+61.9%) to their portfolio in Q1 2026, for an estimated $259,210,941

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$CI Government Contracts

We have seen $3,315,891 of award payments to $CI over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$CI Congressional Stock Trading

Members of Congress have traded $CI stock 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $CI stock by members of Congress over the last 6 months:

REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 03/23.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $15,000 on 12/19 and 1 sale worth up to $15,000 on 03/13.
REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 12/18.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$CI Analyst Ratings

Wall Street analysts have issued reports on $CI in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Guggenheim issued a "Buy" rating on 02/02/2026
Truist Securities issued a "Buy" rating on 01/05/2026

To track analyst ratings and price targets for $CI, check out Quiver Quantitative's $CI forecast page.

$CI Price Targets

Multiple analysts have issued price targets for $CI recently. We have seen 13 analysts offer price targets for $CI in the last 6 months, with a median target of $338.0.

Here are some recent targets:

Andrew Mok from Barclays set a target price of $304.0 on 05/26/2026
A.J. Rice from UBS set a target price of $400.0 on 05/22/2026
Erin Wright from Morgan Stanley set a target price of $361.0 on 05/20/2026
George Hill from Deutsche Bank set a target price of $302.0 on 05/20/2026
Lance Wilkes from Bernstein set a target price of $371.0 on 05/05/2026
Jason Cassorla from Guggenheim set a target price of $338.0 on 05/04/2026
Stephen Baxter from Wells Fargo set a target price of $305.0 on 05/01/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.